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The anthracycline–DNA complex, which is a potent agent for cancer
chemotherapy, has a unique intercalating molecular structure with
preference to the GC bases of DNA, as shown by Rich’s group in
studies of single-crystal x-ray diffraction. Understanding cytotox-
icity and its photoenhancement requires the unraveling of the
dynamics under the solution-phase, physiological condition. Here
we report our first study of the primary processes of drug function.
In a series of experiments involving the drug (daunomycin and
adriamycin) in water, the drug–DNA complexes, the complexes
with the four nucleotides (dGTP, dATP, dCTP, and dTTP), and the
drug-apo riboflavin-binding protein, we show the direct in-
volvement of molecular oxygen and DNA base-drug charge-
separation—the rates for the reduction of the drug and dioxygen
indicate the crucial role of drug/base/O2 in the efficient and
catalytic redox cycling. These dynamical steps, and the subsequent
reactions of the superoxide product(s), can account for the
photoenhanced function of the drug in cells, and potentially for
the cell death.
Drug molecules that target a particular DNA sequence haveshown selectivity to inhibit or modulate gene expression and
are valuable for a variety of chemotherapeutic strategies (1, 2).
Daunomycin (DM), one of the anthracycline antibiotics, is
among the most effective drugs for cancer chemotherapy. Pre-
vious studies of single-crystal molecular structures (3, 4) and
solution-phase binding thermodynamics and kinetics (5, 6) have
demonstrated that DM molecules have preference for the GC
bases of DNA and intercalate into GC base pairs (Fig. 1). It is
also known that the cytotoxicity of DM is enhanced by photo-
activation (7, 8). The understanding of the recognition process
and drug action requires not only the important information
about static molecular structures, but also knowledge of the
elementary steps of dynamics. For a rational design of reactivity
(9), unraveling the dynamics under physiological conditions of
hydration and oxygenation is essential to the function.
In this contribution, we report direct observation of the
primary processes involved in DM and adriamycin (AM) drug
action. It is found that the selective recognition of GC enhances
charge separation with the net transfer of electron to the drug.
Furthermore, we observe a striking effect of dioxygen on the
drug–dGTP nucleotide in water—the presence of O2 depletes
the drug radical population, leading to the formation of super-
oxide anion radicals (see below), whereas its absence leads to
charge recombination to reform the initial state. Because these
reactions were found to be ultrafast in nature, all subsequent
reactions involving dioxygen occur as a result of charge separa-
tion. These processes can account for the photoenhancement of
the drug action in cells, cytotoxicity, and potentially as precur-
sors for the cell death. We discuss the relationship of this effect
of enhanced cell damage to the less efficient thermal reaction
involving a similar transition state. We also report results for
DM-apo riboflavin-binding protein complex, which show the
analogy with DNA hydrophobic recognition, but with redox
cycling due to tryptophans.
Methodology
For thermal reactions, charge separation is a slow process
because of energy-barrier crossing. We used femtosecond (fs)
excitation to induce (over the barrier) electron transfer from the
base to the intercalated (DNA) or complexed (nucleotide) drug.
We then probed, with fs resolution, the evolution of the charge-
transfer state and its subsequent decay, either by charge recom-
bination recovery or by reaction with O2. We have invoked an
elaborate laser setup to study these systems by using transient
absorption and fluorescence up-conversion methods, as de-
scribed (10). Briefly, a fs laser pulse at 480 nm or 510 nm
(controlled, 0.1–0.4 J) was used to excite the drug molecules.
A second fs pulse at800 nm (80 fs and 40 J) was used to probe
the fluorescence emission by mixing it in a 0.2-mm BBO crystal
in the up-conversion experiment. For the transient absorption
experiment a fs probe pulse in the wavelength range 465–700 nm
or at 400 nm was used to measure the absorption transient
induced by the excitation pulse. The polarization of the pump
and probe pulses were set to magic angle conditions (54.7°) to
avoid contributions from orientational motion. The experiments
were performed at room temperature.
Sample Preparation
Mononucleotides (dGTP, dATP, dCTP, and dTTP) and anti-
cancer drugs (DM and AM, 98%) were from Sigma. DNA
double helix is GC homopolymers obtained from Amersham
Pharmacia. The DNA sample was prepared and purified as
described (6). Before further use, the DNA was dialyzed against
a buffer consisting of 6 mM Na2HPO4, 2 mM NaH2PO4, 1 mM
Na2EDTA, and 0.185 M NaCl at pH 7.0 for 24 h. Ambient
oxygen, as well oxygen from a cylinder, was used in experiments
involving the effect on the observed dynamics.
Results and Discussion
The spectroscopy of DM is known (unpublished data; see also
ref. 11): the absorption peak is at 480 nm and the emission
‘‘mirrors’’ the absorption with a peak at 590 nm. The time-
resolved spectra of DM in water are detailed elsewhere: because
the emission bands do not shift to longer wavelength with
increasing polarity, transient solvation of DM by water is minor.
In water, our measured vibrational relaxation time is200 fs and
up to 1 picosecond (ps) and the fluorescence lifetime is 1 ns.
Fig. 2 shows the fs-resolved fluorescence of DM in water, in
the presence of DNA (GC homopolymer), and also with guanine
nucleotide, 2-deoxyguanosine 5-triphosphate (dGTP); not
shown are the other nucleotides studied: dATP, dCTP, and
dTTP and the data for AM. The dramatic change in rates is
evident: DM in water (1 ns), DM-DNA (290 fs; 1.7 ps), and
Abbreviations: DM, daunomycin; AM, adriamycin.
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DM-dGTP (600 fs; 3 ps). The intercalation of DM in DNA is
certain (3–6). This intercalation leads to a dramatic shortening
of the decay time of DM, by 3 orders of magnitude, from 1 ns
to 290 fs. This huge increase in rates is clearly the result of
complexation of the DNA base with the drug and is due to
electron transfer from the base to DM. The major part of the
transfer (63%) occurs in 290 fs; the 1.7-ps component may
reflect the other conformations of unprivileged structures. NMR
studies and theoretical calculations (12, 13) indicate the exis-
tence of two conformations of DM, and the observed time
constant for the electron transfer is consistent with at least two
structurally different complexes. However, charge separation
may involve a distribution of rates due to vibration relaxation
(see above) and also orientation relaxation.
For DM-DNA complexes, the fluorescence signal decays
almost to zero in a few ps. The remaining nanosecond compo-
nent accounts for less than 1% and is due to free DM molecules
in water (14). This large ratio shows that almost all DM
molecules were intercalated into the hydrophobic environment
of GC base pairs at our concentration ratio of 100:1; [base pairs]
 1 mM, [DM] 10 M. The equilibrium constant has recently
been measured (6) and it is 2.6 105 M1, indicating that larger
than 99% of complexes of DM-DNA are formed under our
conditions. For the nucleotides, the equilibrium constant is
significantly smaller and from concentration-dependence of the
time-resolved fluorescence, we estimated it to be 160 M1; the
percentage of complexes formed is 97% at the stated conditions.
For nucleotides, the concentration ratio typically is 9,000:1.
Clearly the concentration of free drugs and their dimers is less
than 1% for DNA and 3% for nucleotides.
The evidence for charge separation comes from several
observations. First, the decay of DM in DNA is similar to that
Fig. 1. Crystal structure of DM-DNA complex. DM, shown as space-filled, intercalates into GC base pairs while the amino sugar ring, daunosamine, fits in the
minor groove. (Upper) The crystal structure obtained from x-ray diffraction by Rich and his group (3). (Lower) The DNA double strand—in our case, a GC
homopolymer.
Qu et al. PNAS  December 4, 2001  vol. 98  no. 25  14213
BI
O
PH
YS
IC
S
CH
EM
IS
TR
Y
observed with the nucleotide dGTP, but vastly different from
that of the free drug in water. Second, the decay rate of DM
in the presence of the four different nucleotides exhibits a
trend consistent with the driving force G0 of the reaction for
electron transfer: the easier the oxidation of the nucleotide,
the faster the rate of electron transfer. Electrochemistry
studies of DM give the reduction potential [DM/DM is
0.38  0.08 V vs. NHE Standard (ref. 15 and references
therein)] and knowing the oxidation potential of the base
[G/G  1.4 V vs. NHE (16–18)] and the energy of 0, 0
transition (2.3 eV; 1 eV  1.602  1019 J), we obtained a net
G0 of 0.5 eV. Similarly, we obtained G0 for the other
bases; the rate is largest for dGTP, then for dATP (reaction
time, 18 ps and 60 ps), and the rates for dTTP and dCTP are
slower than (1 ns)1. We also investigated the involvement of
other possible processes. From our results the following pro-
cesses can be excluded: proton transfer, resonance energy
transfer, internal conversion, and intersystem crossing. We
observed no noticeable change with D2OH2O solution and
with pH 5–7; the drug lifetime in different solvents is still on
the nanosecond scale, and the absorption of bases does not
overlap with the drug emission. There is also a direct evidence;
namely, the observation of the charge-separated state—its
formation, and recombination and reaction.
In Fig. 3, we display the striking change in the ground-state
transient absorption (ext  510 nm; probe  480 nm) of
DM-dGTP in the presence and absence of dioxygen. In both
cases, we first observe negative absorption. At room tempera-
ture, the concentration of O2 is1 mM in water. On purging with
argon to remove O2, the observed signal shows a rise from
negative to positive. In the presence of oxygen, either in the
water solution or by bubbling it through the sample, the positive
absorption disappears. It is important to note that we have
repeated the fluorescence decay measurements with and without
O2 for DM-dGTP and observed no change (see Fig. 3), indi-
cating that the forward rate for charge separation is unaffected
by oxygen. Also, note that the observed negative absorbance is
not due to stimulated emission because our pump pulse (510 nm)
was at lower energy than the probe pulse (480 nm) and we only
monitored the change in absorption of the probe (480 nm).
The above observations elucidate the elementary steps in-
volved in the mechanism:
DM-G 3 DM*-G 3 DM-G (singlet) [1a]
DM-G (singlet) 3 DM-G [1b]
DM-G (singlet) 3 DM-G (triplet) [1c]
DM-G (triplet)O2 3 DM-G  O2
 [1d]
Fig. 3 contains the analysis of the population flow described by
Eqs. 1a–d. With oxygen, the rise of the negative absorption of
DM-dGTP was observed in 600 fs and 3 ps, and certainly the
signal was back to almost zero in at most 10 ps. This indicates that
the signal is due to the formation and recombination to the
ground state of the singlet charge transfer state and that the rate
of this recovery is not larger than (10 ps)1. In the absence of
oxygen, the absorption rises from negative to positive values,
then decays in35 ps, which may imply a recovery with this time
constant. However, careful measurements of the positive ab-
sorption as a function of pump laser power (and using cw vs.
pulsed lasers), cell thickness, and stirring of the solution indi-
cated that this signal is produced as a result of a long-lived triplet
species, with lifetime shorter than a millisecond, as determined
by our repetition rate; it quenches effectively with O2. The minor
product contribution (resulting from the triplet state) is moni-
tored by its absorption at 510 nm, and the 35-ps decay is from
the probe signal at 480 nm; the product is formed by a diffusion-
controlled bimolecular reaction, likely to form complexes of
reduced DM dimers (or with other moeities) that have absorp-
tion similar to DM but red shifted, as we observed experimen-
tally. It should be emphasized that such fs–ps transient behavior
was absent for samples of the nucleotide or the drug alone in
solution—in fact we observed only the coherence spike for the
former and the negative absorption (ns) for the latter. Accord-
ingly, we have observed channel (Eq. 1d) with a long-lived charge
separated state capable of producing the superoxide.
These results show the direct involvement of oxygen. In water
and at room temperature, a diffusion-controlled process will give
a decay time close to a microsecond for a bimolecular encounter
with O2, faster than the lifetime on the millisecond or longer
scale. The redox property of DM and O2 supports this picture:
the potential for DM/DM is 0.4 V (ref. 15 and references
therein) and for O2/O2 is 0.16 V in water (19), thus the
driving force is favorable. From the steady-state redox chemistry
of anthracyclines, it has been reported that redox recycling,
which begins with the formation of the DM radical and the
following reaction with oxygen to generate superoxide, is an
important aspect of drug cytotoxicity (ref. 15, and references
therein, and ref. 20). In our studies, the key is the direct,
enhanced reduction of the drug and the clocking of subsequent
reactions.
Fig. 2. Fluorescence up-conversion decays for drug DM (10 M) in water
(610 nm); with DNA (base pairs 1 mM); and with nucleotide dGTP (90 mM).
GC homopolymer was prepared as described in ref. 6. The buffer used
consisted of 6 mM Na2HPO4, 2 mM NaH2PO4, 1 mM Na2EDTA, and 0.185 M
NaCl at pH 7.0 for all samples. Details of the experimental apparatus are
given in ref. 10. The measured decay time constants are given for the three
cases (see text).
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With AM, we have obtained similar results for the time
scales involved in charge separation, indicating that the pri-
mary processes for both drugs are of a similar nature. The
molecular structures of the drugs (Scheme 1) differs only in
one of the terminal substituents, suggesting that subsequent
reactions involving O2 that account for the difference in
cytotoxicity may involve the hydrogen migration through
enediol tautomerization. The experiments on DNA–drug
complexes show a faster time for charge separation, ref lecting
the 3-Å short separation between GC and the drug in the
confined intercalation site, in contrast with the less confined
nucleotide complexes. The positive absorption was not ob-
served for the DNA case, but the recovery of the negative
absorption was still occurring in 5 ps. This finding is con-
sistent with G-hole migration to the neighboring site(s)
DM-G-C-G; the latter is known to be on the ps time scale
(10, 21) and can result in DNA cleavage (22).
As with DNA, many proteins have hydrophobic domains. To
test for the applicability of the above mechanism in proteins we
also carried out a series of experiments for DM in the apo
ribof lavin-binding protein (chicken egg white). The crystal
structure is known (23) and there are several tryptophan
residues in the hydrophobic pocket. These residues, similar to
G, have the ability to donate electrons (tryptophan/
tryptophan  1.15 V (24); net G0  0.75 eV). We
observed similar dynamical behavior in the DNA and protein
systems, with and without oxygen, except for a change by a
factor of 3 in the electron transfer rates—the drug–DNA
Scheme 1. Molecular structure of DM and AM drugs.
Fig. 3. Transient absorption decays of DM-dGTP nucleotide in the absence and presence of dioxygen; the ratio of nucleotide to drug concentration is 900. The
best theoretical fits are shown as solid lines. Note the positive absorbance when O2 is absent. (Inset) The states described by the steps in Eq. (1). (Upper Inset)
The fluorescence decays (using up-conversion) with and without oxygen (no change).
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complex is more efficient, likely due to a more perfect
chelation. In the protein, the rates decrease as we increase the
degree of unfolding by changing the concentration of the
denaturing agent (Fig. 4). The drug DM behaves as in water
(see Fig. 2) when the concentration of the agent reaches 2 M,
entirely consistent with the effect of binding and charge
separation in the confined environment.
In living cells, previous studies have shown that DM cyto-
toxicity is significantly enhanced by laser photoactivation (7,
8). However, the cause of the enhancement was not clear. With
the mechanism we report here, we can elucidate the drug
function. The photoexcitation enhances the rate of charge
separation over that of the thermal reaction (barrier crossing)
and triggers a redox cycling with a much higher efficiency, thus
resulting in enhanced cell killing by the anticancer drug. The
reaction with oxygen guarantees the success of trajectories
forming the superoxide even for the slow encounter charac-
teristics of thermal reactions. Our ultrafast rate of charge
separation is for excitation at   510 or 480 nm, and it is
remarkable that the photoactivated cytotoxicity was found
efficient at 514 nm. Moreover, the product for in vitro drug
solutions, excited at 438 nm, was spin-trapped and found to be
O2, which decays to give hydroxyl radicals (25).
In general, it has been reported that this class of drugs can
stimulate topoisomerase II-mediated DNA cleavage by inducing
structural alterations of the DNA intercalation sites; ternary
complex of topo II/drug/DNA have been isolated (ref. 15, and
references therein, and ref. 26). This process can cause deletions,
insertions, and chromosomal aberrations and trigger lethal path-
ways in damaged cells and finally kill cancerous cells (27, 28).
Our results of ultrafast electron transfer between guanine (small-
er rate for A, C, and T) and the drug and the direct role of
molecular oxygen suggest that this redox activation can trigger
damage and may stimulate topoisomerase II poisons, which can
ultimately lead to cell death (Scheme 2).
The enhanced effect induced by light is thus due to the
energetically and kinetically favored reaction over the barrier.
Both the thermal and photoactivated reactions are likely to have
similar transition states, as dictated by state correlations involv-
ing ionic potentials (29, 30). The extension of our studies to other
drug/DNA systems is needed before generalization can be made.
However, the results reported here clearly elucidate the role of
charge separation and the biologically reactive molecular oxy-
gen. The intercalation with DNA is important for equilibrium
properties (equilibrium constant and G0), but the primary
function of the drug cannot be fully revealed without knowledge
of the dynamics that control the subsequent steps for the
disruption of DNA and RNA synthesis. Currently we are study-
ing different types of DNA in the hope of generalizing the above
picture for the molecular basis of clinical observations.
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